The table below shows BIOMARIN PHARMACEUTICAL INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$827.99M
$572.84M
$159.26M
$175.90M
$304.54M
$85.36M
Capital expenditure
$103.04M
$85.42M
$96.69M
$120.96M
$95.58M
$114.31M
Investing cash flow
-$414.24M
$136.49M
-$111.24M
-$20.03M
-$366.31M
-$53.62M
Dividends paid
-
-
-
-
-
-
BMRN operating cash flow (10-K history)
BIOMARIN PHARMACEUTICAL INC reported operating cash flow of $827.99M for fiscal year 2025. That is up 44.5% from $572.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$227.84M (FY 2016) to $827.99M. Figures come from the company's audited annual reports as filed with the SEC.
